Our Pipeline and Products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.

Share your partnering idea

Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.

 

Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.

Our Values

Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.

 

What does it really make Menarini unique? The diversity and authenticity of our key resource - the People.
Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.

Available positions on Linkedin

Menarini employees make all the difference, every day.

 

News

Tomorrow in Florence, the convention organised to celebrate the Menarini Group’s 125th anniversary

 

Florence, 23 February 2011

PRESS RELEASE

Tomorrow in Florence, the convention organised
to celebrate the Menarini Group’s 125th anniversary

Florence, 23 February 2011 – To be held in Florence tomorrow, the event ‘Menarini’s research: today’s value, tomorrow’s challenges’, to celebrate the 125 years of the Menarini Group’s history and pharmaceutical research.
The meeting will be held in the Salone dei Cinquecento in Palazzo Vecchio, with the Mayor of Florence, Matteo Renzi giving the welcoming speech.
A large turnout is expected, with institutional representatives, journalists, and leading figures from the scientific community.
Backed by the presence of prominent names in the world of medicine and research, the Menarini Group will retrace its 125 years’ of history with an eye to the future. It will address the developments in the action mechanism of nitric oxide, focusing on the Mimosa Study regarding the prevention of possible relapses of ovarian cancer, and illustrating the new frontiers of Menarini’s research.
Distinguished guests will include Louis J. Ignarro, Nobel Prize for Medicine and Physiology, Jonathan S. Berek of the Stanford University, Sergio Dompè, President of Farmindustria, and Domenico Regoli of the University of Ferrara. Speakers from the Menarini Group will include Carlo Alberto Maggi, Director of Research and Development, Angela Capriati, Director of Clinical Research, and Andrew Slade, President of Menarini Biotech, while Enrico Garaci, President of the Higher Health Institute, and Gianfranco Gensini, Dean of the School of Medicine of the University of Florence will be moderating.
The event can also be visited on the Menarini Group’s company website: www.menarini.com

A preliminary meeting will be held with journalists at 11.30 in the Salone de’ Dugento in Palazzo Vecchio.

For more information please contact Press Office